El Jurdi N, Blazar BR, Pavletic SZ. Chronic graft-versus-host disease, Part 2: clinical success and roadmap to the future. Transplantation. 2025;109:e446–e54.
Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood J Am Soc Hematol. 2013;121:5098–103.
Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB1R antagonists. Pharm Ther. 2020;208:107477.
Cinar R, Gochuico BR, Iyer MR, Jourdan T, Yokoyama T, Park JK, et al. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight. 2017;2:e92281.
Cinar R, Basu A, Arif M, Park JK, Zawatsky CN, Zuo BLG, et al. Anandamide is a potential blood biomarker of Hermansky-Pudlak syndrome pulmonary fibrosis. Am J Respir Crit Care Med. 2025;211:650–4.
Cinar R, Park JK, Zawatsky CN, Coffey NJ, Bodine SP, Abdalla J, et al. CB1R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky–Pudlak syndrome. Clin Transl Med. 2021;11:e471.
Basu A, Arif M, Wolf KM, Behee M, Johnson N, Pommerolle L, et al. Targeting cannabinoid receptor 1 for antagonism in pro-fibrotic alveolar macrophages mitigates pulmonary fibrosis. JCI Insight. 2025;10:e187967.
Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–79.
Basu A, Pommerolle L, Arif M, Meliton AY, Udofia I, Wu D, et al. Elevated blood anandamide levels in acute COVID-19 pneumonia with respiratory failure. Am J Med Sci. 2025;370:271–7.
Yuan CY, Zhou V, Sauber G, Stollenwerk T, Komorowski R, López A, et al. Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease. Blood J Am Soc Hematol. 2021;137:1241–55.
Goklemez S, Im AP, Cao L, Pirsl F, Steinberg SM, Curtis LM, et al. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis. Am J Hematol. 2020;95:387–94.
Knop FK, Kunos G, Dicker D, Paquette JS, Aronne L, Frenkel O, et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Lancet Diab Endocrinol. 2025;13:911–23.
